Subcutaneous mAb May Benefit High-Risk Outpatients With COVID-19 - HealthDay News
4/12/2022 12:00:00 AM3 yearsago
by Physician’s Briefing Staff
by Physician’s Briefing Staff
SC casirivimab and imdevimab linked to reduced 28-day hospitalization or death for high-risk outpatients with mild to moderate COVID-19
TUESDAY, April 12, 2022 (HealthDay News) -- For high-risk outpatients with mild-to-moderate COVID-19, subcutaneously administered monoclonal antibody (mAb) treatment with casirivimab and imdevimab is… [+1671 chars]
full article...